ストックスクリーナーアプリを入手
10.20
3.22%
-0.3399
アフターアワーズ：
9.85
-0.3501
-3.43%
Envveno Medical Corp (NVNO) 最新ニュース
Insider Selling: Francis Duhay Sells Shares of enVVeno Medical C - GuruFocus
Director at enVVeno Medical (NASDAQ: NVNO) sells 140 shares under Rule 10b5-1 plan - Stock Titan
[144] enVVeno Medical Corp SEC Filing - Stock Titan
enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System - PhillyBurbs
enVVeno Medical Announces Reverse Stock Split - Great Falls Tribune
enVVeno Medical (NVNO) Holds Steady at $10.75 – Support and Resistance Define Neutral RangeUndervalued Stocks - newsline.com
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series - ACCESS Newswire
EnVVeno Medical to Participate in the Virtual Investor Closing Bell Series - marketscreener.com
First FDA IDE venous valve study: enVVeno CEO Q&A June 9 - Stock Titan
enVVeno Medical (NVNO) Edges Higher as Stock Tests Key Resistance Near $11.90Throwback Trade - The Legal Advocate
enVVeno Medical (NVNO) Edges Lower as Stock Holds Above Key SupportFRAMA Signal - newsline.com
enVVeno Medical (NVNO) Slips 1.03% as Price Hovers Near Key Support at $10.47Factor Crowding - newsline.com
NVNO Q3 2025 Earnings: Narrower Net Loss Surpasses Analyst ExpectationsEarnings Season Review - The Legal Advocate
This Tiny Medical-Device Stock Is Back Above $11. Its Next FDA Test Is the Whole Trade - Bez Kabli
enVVeno Medical Q3 2025 Earnings: Narrower Loss Beats Expectations as Clinical Programs AdvanceProfit Margin Analysis - The Legal Advocate
enVVeno Medical (NVNO) Q3 2025 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Progress - newsline.com
enVVeno Medical (NVNO) Edges Higher: Analyzing Recent Price Action and Key LevelsWave Truncation - Newser
Perceptive entities disclose 9.99% stake in enVVeno (NASDAQ: NVNO) - Stock Titan
This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It? - MSN
Kingdon group holds 36,166 shares in enVVeno (NASDAQ: NVNO) - Stock Titan
Number of shareholders of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
enVVeno Medical Discusses FDA IDE Approval in Virtual Investor "What This Means" Segment - The Joplin Globe
First-ever U.S. venous valve trial could address DVI in 3M Americans - Stock Titan
enVVeno Medical Corporation: enVVeno Medical Discusses FDA IDE Approval in Virtual Investor What This Means Segment - FinanzNachrichten.de
TradingKey - TradingKey
What enVVeno (NVNO) is doing that smart investors recognize (-2.26%) 2026-05-08Stock Surge - Newser
enVVeno Medical sees cash runway into 3Q27 - TipRanks
enVVeno Medical says cash burn rate may increase to $4M-$5M per quarter - TipRanks
enVVeno Medical reports Q1 EPS ($5.89) vs. ($7.75) last year - TipRanks
enVVeno Reports Having $25M Cash on Hand in Q1 Earnings - Orange County Business Journal
enVVeno Medical Reports First Quarter 2026 Financial Results and Provides Business Update Highlighting Strategic Advancement of the enVVe System - IndyStar
With $25M on hand, enVVeno moves toward first U.S. venous valve study - Stock Titan
EnVVeno Medical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
enVVeno Medical (NVNO) trims Q1 loss and secures FDA IDE for pivotal enVVe TAVVE study - Stock Titan
One enVVeno Medical Insider Raised Their Stake In The Previous Year - Yahoo Finance
enVVeno Medical Receives FDA IDE Approval for Non-Surgical Replacement Venous Valve - MedTech Intelligence
enVVeno Medical secures FDA IDE approval for venous valve study - Medical Device Network
enVVeno Medical (NVNO) Secures FDA IDE Approval for Pivotal Stud - GuruFocus
enVVeno Medical announces FDA awarded IDE approval to proceed with TAVVEB study - TipRanks
enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve - BioSpace
enVVeno Medical Wins FDA IDE for TAVVE Trial - TipRanks
enVVeno receives FDA approval for venous valve pivotal trial By Investing.com - Investing.com South Africa
enVVeno receives FDA approval for venous valve pivotal trial - Investing.com
FDA clears enVVeno (NASDAQ: NVNO) pivotal enVVe CVI valve study - Stock Titan
FDA allows first U.S. study of a nonsurgical vein valve for 3M patients - Stock Titan
enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement - Times Reporter
2.43%
大文字化:
|
ボリューム (24 時間):